In the absence of a trial, a matched analysis compared cancer control after salvage focal therapy vs radical prostatectomy (RP) for radiorecurrent prostate cancer.
A trial evaluated the short-term oncologic efficacy of cooled focal therapy ablation using the ProFocal device in men with localized, intermediate-risk prostate cancer.
(HealthDay News) — More than four in 10 people older than 50 years (42 percent) have not gotten either a flu or COVID-19 vaccine, according to the results of a survey conducted by the University of ...
A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...
In patients with AAV, 2 of the novel inflammatory biomarkers evaluated—the Systemic Immune-Inflammatory Index and the Systemic Inflammatory Response Index—recovered after AAV disease-inducing ...
Significantly higher sensitivity seen, while specificity was lower for AI-augmented system versus standard of care of analog auscultation.
The FDA has given the green light to beetroot red and has also sanctioned the use of spirulina extract. (HealthDay News) — ...
Studies on whether pelvic lymph node dissection (PLND) provides a survival benefit in men with prostate cancer having surgery ...
Comprehensive phosphorus management preserves residual renal function, considers dialysis modality, and minimizes intervention burden.
A study supports targeted conversion of kidney transplant recipients with a history of cutaneous squamous cell carcinoma ...
A phase 3 trial of ferric citrate supports its use as a treatment for iron deficiency anemia in non-dialysis chronic kidney disease (CKD).
ONCO-ACS score predicts risk for all-cause mortality, major bleeding, and ischemic events in patients with cancer and acute coronary syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results